NORDIC BIOSCIENCE HOLDING A/S - Group

 

Quicksearch
from your own companies




Analyst: XBRLDenmarkIFRS
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  19.3% 19.0% 0.9% 3.1% 1.3%  
Credit score (0-100)  6 6 90 56 80  
Credit rating  B B A BBB A  
Credit limit (mDKK)  0.0 0.0 13.5 0.0 9.9  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  238 225 294 190 527  
Gross profit  238 225 296 132 466  
EBITDA  79.6 37.4 51.0 -17.6 198  
EBIT  79.6 37.4 51.0 -17.6 198  
Pre-tax profit (PTP)  79.6 37.4 51.6 -21.2 209.8  
Net earnings  79.6 37.4 51.6 12.3 170.8  
Pre-tax profit without non-rec. items  79.6 37.4 51.6 -21.2 210  

 
See the entire income statement

Balance sheet (mDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 76.1 78.8 75.2  
Shareholders equity total  137 57.8 61.6 44.1 231  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 0.0 228 289 720  

Net Debt  0.0 0.0 -60.6 -81.9 -455  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  238 225 294 190 527  
Net sales growth  5.2% -5.4% 30.6% -35.2% 176.9%  
Gross profit  238 225 296 132 466  
Gross profit growth  5.2% -5.4% 31.6% -55.3% 251.6%  
Employees  219 151 168 171 176  
Employee growth %  16.5% -31.1% 11.3% 1.8% 2.9%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 228 289 720  
Balance sheet change%  0.0% 0.0% 0.0% 26.4% 149.6%  
Added value  79.6 37.4 51.0 -17.6 197.7  
Added value %  33.5% 16.6% 17.3% -9.3% 37.5%  
Investments  0 0 85 2 -8  

Net sales trend  1.0 -1.0 1.0 -1.0 1.0  
EBIT trend  4.0 5.0 5.0 -1.0 1.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  33.5% 16.6% 17.3% -9.3% 37.5%  
EBIT %  33.5% 16.6% 17.3% -9.3% 37.5%  
EBIT to gross profit (%)  33.5% 16.6% 17.2% -13.3% 42.5%  
Net Earnings %  33.5% 16.6% 17.6% 6.5% 32.4%  
Profit before depreciation and extraordinary items %  33.5% 16.6% 17.6% 6.5% 32.4%  
Pre tax profit less extraordinaries %  33.5% 16.6% 17.6% -11.1% 39.8%  
ROA %  0.0% 0.0% 22.6% -5.1% 42.4%  
ROI %  18.9% 19.2% 31.9% -13.8% 119.3%  
ROE %  18.9% 19.2% 43.2% 23.3% 124.2%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  50.0% 50.0% 26.7% 15.3% 32.1%  
Relative indebtedness %  -57.6% -25.7% 56.7% 128.4% 92.8%  
Relative net indebtedness %  -57.6% -25.7% 36.1% 85.3% 6.4%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -119.0% 464.8% -230.3%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  -0.0 -0.0 1.0 0.7 1.2  
Current Ratio  -0.0 -0.0 1.2 0.8 1.3  
Cash and cash equivalent  0.0 0.0 60.6 81.9 455.4  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 47.7 40.7 57.4  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 48.9% 83.9% 108.7%  
Net working capital  137.1 57.8 22.2 -38.6 124.6  
Net working capital %  57.6% 25.7% 7.6% -20.3% 23.6%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  1 1 2 1 3  
Added value / employee  0 0 0 -0 1  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -0 1  
EBIT / employee  0 0 0 -0 1  
Net earnings / employee  0 0 0 0 1